Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency - PubMed (original) (raw)
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency
Takashi Shigematsu et al. Am J Kidney Dis. 2004 Aug.
Abstract
Background: Fibroblast growth factor 23 (FGF-23) is a recently identified polypeptide that promotes renal phosphate excretion and decreases serum 1,25-dihydroxyvitamin D3 (1,25D) levels. Serum FGF-23 levels are extraordinarily elevated in patients with end-stage renal failure.
Methods: Blood and urine samples were obtained from 62 predialysis patients (age, 51.3 +/- 14.0 years; range, approximately 18 to 76 years; 32 men, 30 women). Serum FGF-23 levels were determined by means of a sandwich enzyme-linked immunosorbent assay system using 2 kinds of monoclonal antibodies that does not detect biologically inactive N-terminal and C-terminal fragments derived from an identified internal cleavage site to date.
Results: Serum FGF-23 levels increased with the decrease in creatinine clearance (Ccr). Both intact parathyroid hormone (PTH) and 1-84 PTH levels correlated closely with FGF-23 levels (r2 = 0.857; r2 = 0.860). A negative correlation between serum concentrations of FGF-23 and 1,25D (r2 = 0.255) was found. The maximum tubular reabsorptive rate of phosphate correlated negatively with serum FGF-23 concentrations (r2 = 0.460). However, the amount of daily urinary phosphate excretion was significantly less in patients with a Ccr less than 30 mL/min (<0.50 mL/s; P < 0.01), whereas their circulating FGF-23 levels were significantly greater (P < 0.001).
Conclusion: Circulating FGF-23 levels increase with the decrease in renal function. FGF-23 is a likely candidate to lead the reduction in serum 1,25D levels. FGF-23 becomes a potential uremic toxin to decrease 1,25D levels when it loses its hypophosphatemic action because of a decreased number of viable nephrons in patients with advanced renal failure. As such, FGF-23 may be an important determinant in the regulation of mineral metabolism with renal insufficiency.
Similar articles
- Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.
Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M. Nakanishi S, et al. Kidney Int. 2005 Mar;67(3):1171-8. doi: 10.1111/j.1523-1755.2005.00184.x. Kidney Int. 2005. PMID: 15698459 - Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y. Evenepoel P, et al. Clin J Am Soc Nephrol. 2010 Jul;5(7):1268-76. doi: 10.2215/CJN.08241109. Epub 2010 May 6. Clin J Am Soc Nephrol. 2010. PMID: 20448073 Free PMC article. - [Biological activity of FGF-23 and pathophysiologic role in chronic kidney disease].
Yamashita T. Yamashita T. Clin Calcium. 2004 May;14(5):760-3. Clin Calcium. 2004. PMID: 15577039 Review. Japanese.
Cited by
- Fibroblast Growth Factor-23 (FGF-23) in Dogs-Reference Interval and Correlation with Hematological and Biochemical Parameters.
Lapsina S, Nagler N, Müller SF, Holtdirk A, Kottmann T, Müller E, Schäfer I. Lapsina S, et al. Animals (Basel). 2023 Oct 13;13(20):3202. doi: 10.3390/ani13203202. Animals (Basel). 2023. PMID: 37893926 Free PMC article. - Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects.
Komaba H. Komaba H. Clin Exp Nephrol. 2023 May;27(5):395-401. doi: 10.1007/s10157-023-02336-y. Epub 2023 Mar 28. Clin Exp Nephrol. 2023. PMID: 36977891 Free PMC article. Review. - Associations between endogenous sex hormones and FGF-23 among women and men in the Multi-Ethnic Study of Atherosclerosis.
Ogunmoroti O, Osibogun O, Zhao D, Mehta RC, Ouyang P, Lutsey PL, Robinson-Cohen C, Michos ED. Ogunmoroti O, et al. PLoS One. 2022 May 25;17(5):e0268759. doi: 10.1371/journal.pone.0268759. eCollection 2022. PLoS One. 2022. PMID: 35613118 Free PMC article. - Fibroblast Growth Factor 23 as Regulator of Vitamin D Metabolism.
Nakatani S, Nakatani A, Mori K, Emoto M, Inaba M, Razzaque MS. Nakatani S, et al. Adv Exp Med Biol. 2022;1362:47-54. doi: 10.1007/978-3-030-91623-7_6. Adv Exp Med Biol. 2022. PMID: 35288872 - FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions.
Ivey-Miranda JB, Stewart B, Cox ZL, McCallum W, Maulion C, Gleason O, Meegan G, Amatruda JG, Moreno-Villagomez J, Mahoney D, Turner JM, Wilson FP, Estrella MM, Shlipak MG, Rao VS, Testani JM. Ivey-Miranda JB, et al. Circ Heart Fail. 2021 Nov;14(11):e008385. doi: 10.1161/CIRCHEARTFAILURE.121.008385. Epub 2021 Oct 25. Circ Heart Fail. 2021. PMID: 34689571 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials